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Summary
Background Diabetes has been deﬁ ned on the basis of diﬀ erent biomarkers, including fasting plasma glucose (FPG), 
2-h plasma glucose in an oral glucose tolerance test (2hOGTT), and HbA1c. We assessed the eﬀ ect of diﬀ erent 
diagnostic deﬁ nitions on both the population prevalence of diabetes and the classiﬁ cation of previously undiagnosed 
individuals as having diabetes versus not having diabetes in a pooled analysis of data from population-based health 
examination surveys in diﬀ erent regions.
Methods We used data from 96 population-based health examination surveys that had measured at least two of the 
biomarkers used for deﬁ ning diabetes. Diabetes was deﬁ ned using HbA1c (HbA1c ≥6·5% or history of diabetes 
diagnosis or using insulin or oral hypoglycaemic drugs) compared with either FPG only or FPG-or-2hOGTT 
deﬁ nitions (FPG ≥7·0 mmol/L or 2hOGTT ≥11·1 mmol/L or history of diabetes or using insulin or oral 
hypoglycaemic drugs). We calculated diabetes prevalence, taking into account complex survey design and survey 
sample weights. We compared the prevalences of diabetes using diﬀ erent deﬁ nitions graphically and by regression 
analyses. We calculated sensitivity and speciﬁ city of diabetes diagnosis based on HbA1c compared with diagnosis 
based on glucose among previously undiagnosed individuals (ie, excluding those with history of diabetes or using 
insulin or oral hypoglycaemic drugs). We calculated sensitivity and speciﬁ city in each survey, and then pooled 
results using a random-eﬀ ects model. We assessed the sources of heterogeneity of sensitivity by meta-regressions 
for study characteristics selected a priori.
Findings Population prevalence of diabetes based on FPG-or-2hOGTT was correlated with prevalence based on FPG 
alone (r=0·98), but was higher by 2–6 percentage points at diﬀ erent prevalence levels. Prevalence based on HbA1c was 
lower than prevalence based on FPG in 42·8% of age–sex–survey groups and higher in another 41·6%; in the other 
15·6%, the two deﬁ nitions provided similar prevalence estimates. The variation across studies in the relation between 
glucose-based and HbA1c-based prevalences was partly related to participants’ age, followed by natural logarithm of 
per person gross domestic product, the year of survey, mean BMI, and whether the survey population was national, 
subnational, or from speciﬁ c communities. Diabetes deﬁ ned as HbA1c 6·5% or more had a pooled sensitivity of 
52·8% (95% CI 51·3–54·3%) and a pooled speciﬁ city of 99·74% (99·71–99·78%) compared with FPG 7·0 mmol/L or 
more for diagnosing previously undiagnosed participants; sensitivity compared with diabetes deﬁ ned based on FPG-
or-2hOGTT was 30·5% (28·7–32·3%). None of the preselected study-level characteristics explained the heterogeneity 
in the sensitivity of HbA1c versus FPG.
Interpretation Diﬀ erent biomarkers and deﬁ nitions for diabetes can provide diﬀ erent estimates of population 
prevalence of diabetes, and diﬀ erentially identify people without previous diagnosis as having diabetes. Using an 
HbA1c-based deﬁ nition alone in health surveys will not identify a substantial proportion of previously undiagnosed 
people who would be considered as having diabetes using a glucose-based test.
Funding Wellcome Trust, US National Institutes of Health.
Copyright © NCD Risk Factor Collaboration. Open Access article distributed under the terms of CC BY.
Introduction
Diabetes prevalence and diabetes-related deaths are 
rising in most parts of the world, at least partly fuelled by 
the worldwide increase in excess weight and adiposity.1–5 
This trend has created concerns about the health and 
functional consequences for patients, and costs for 
health systems.6–8 Tracking the epidemic and the 
progress of programmes aimed at reducing diabetes and 
its complications requires consistent and comparable 
measurement of the prevalence of diabetes and the 
coverage of drug and lifestyle interventions that slow 
diabetes progression and decrease the risk of 
complications.
Diﬀ erent biomarkers have been used to deﬁ ne 
diabetes, including fasting plasma glucose (FPG), 2-h 
plasma glucose in an oral glucose tolerance test 
(2hOGTT), and, more recently, HbA1c.9–15 Population-
based health surveys in diﬀ erent countries and at 
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diﬀ erent times have also used diﬀ erent biomarkers for 
glycaemia and diabetes, and thus deﬁ ne diabetes 
diﬀ erently. The variety of biomarkers and deﬁ nitions 
creates a challenge in consistently analysing diabetes 
prevalence across countries and over time, and in 
measuring what proportion of people with diabetes are 
diagnosed and receive eﬀ ective treatments for diabetes 
and its complications.1,16,17 Therefore, there is a need to 
understand how the use of diﬀ erent biomarkers and 
deﬁ nitions aﬀ ects the identiﬁ cation of diabetes cases 
and the resulting estimates of population prevalence. 
This need is particularly pressing because two of the 
nine global targets for non-communicable diseases set 
after the 2011 United Nations high-level meeting on 
non-communicable diseases require estimates of 
diabetes prevalence: to halt the rise in the prevalence of 
diabetes, and to achieve a 50% coverage of drug 
treatment and counselling, including glycaemic control, 
to prevent coronary heart disease and stroke in people at 
high risk of cardiovascular disease.4,18 Diabetes is also 
one of the four main non-com municable diseases for 
which there is a global target of 25% reduction in 
premature mortality by 2025 compared with 2010.4,18
Some studies have analysed the classiﬁ cation of 
individuals as having diabetes or compared prevalence 
estimates based on diﬀ erent deﬁ nitions in speciﬁ c 
cohorts, especially for HbA1c compared with either FPG 
or 2hOGTT.19–61 Most of these analyses were based on a 
single cohort and very few covered diﬀ erent geographical 
regions. Two pooled analyses of Asian and European 
cohorts, and a study in the Paciﬁ c and Indian Ocean 
islands, assessed how the prevalence of diabetes and the 
classiﬁ cation of individuals as having diabetes versus 
not having diabetes changed depending on whether 
diabetes was deﬁ ned by FPG or 2hOGTT.62–66 There is no 
pooling study for HbA1c, which can be measured easily 
in population-based surveys without the need for 
overnight fasting and has been approved by the 
American Diabetes Association and WHO as a 
diagnostic test for diabetes.11,14 However, a review of data 
from six countries reported that the sensitivity of 
diabetes diagnosis based on HbA1c compared with FPG 
ranged from 17% to 78%,67 raising concerns about ethnic 
variation of HbA1c-based deﬁ nition.17
We assessed the eﬀ ect of diagnostic deﬁ nitions both on 
the identiﬁ cation of diabetes in previously undiagnosed 
individuals and on the population prevalence estimates 
for diabetes in a pooled analysis of data from population-
based health examination surveys in diﬀ erent world 
regions.
Research in context
Evidence before this study
We reviewed studies included in the NCD Risk Factor 
Collaboration databases for comparisons of various diabetes 
deﬁ nitions. We also searched PubMed with the term ((A1c[Title/
Abstract]) AND Sensitivity[Title/Abstract]) AND Speciﬁ city[Title/
Abstract]) on April 13, 2015. We also searched the references of 
recent reviews and guidelines. We found some studies on the 
classiﬁ cation of individuals as having diabetes or on comparison 
of prevalence estimates based on diﬀ erent deﬁ nitions in speciﬁ c 
cohorts, especially for HbA1c compared with either fasting plasma 
glucose (FPG) or 2-h oral glucose tolerance test (2hOGTT). Most 
of these analyses were based on a single cohort and very few 
covered diﬀ erent world regions. Two pooled analyses of Asian and 
European cohorts, and a study in the Paciﬁ c and Indian Ocean 
islands, assessed how the prevalence of diabetes and the 
classiﬁ cation of individuals as having diabetes versus not having 
diabetes changed depending whether diabetes was based on FPG 
or on 2hOGTT. There is no pooling study for HbA1c and we 
identiﬁ ed only one review of data from six countries. Other 
studies compared diﬀ erent diabetes deﬁ nitions among people 
with speciﬁ c pre-existing diseases—eg, heart disease and 
tuberculosis. We also found some prospective studies that 
assessed how HbA1c predicts future incidence of diabetes or 
cardiovascular diseases with mixed results.
Added value of this study
This study is the ﬁ rst pooling of a large number of 
population-based data from diﬀ erent world regions that 
addresses how diﬀ erent deﬁ nitions of diabetes aﬀ ect both the 
total prevalence, and the identiﬁ cation of previously 
undiagnosed individuals. By pooling a large number of data 
sources, the overall meta-analytical ﬁ nding overcomes 
between-study variation, which can be probed in meta-
regressions. Furthermore, by having a large number of 
studies, and age–sex groups within each study, we were able 
to develop regressions to convert across diﬀ erent diabetes 
deﬁ nitions, which is essential for enhancing comparability 
over time and across countries in surveillance.
Implications of all the available evidence
The use of HbA1c in surveillance requires further consideration 
in terms of how it predicts, and helps prevent, diabetes 
complications and sequelae. As such studies are done, and to 
maximise comparability of results across surveys, the best 
approach in population-based health surveys is to measure 
FPG and deﬁ ne diabetes as FPG 7·0 mmol/L or more or history 
of diagnosis with diabetes or using insulin or oral 
hypoglycaemic drugs, as used in the global monitoring 
framework for prevention and control of non-communicable 
diseases. When HbA1c is used, it would be valuable to also 
measure FPG in a subsample of participants to provide 
information about how the two tests relate. The conversion 
regressions developed here can be used to convert prevalence 
based on FPG to that based on FPG-or-2hOGTT. 
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Methods
Study design
We aimed to answer two questions. First, how does the 
estimated prevalence of diabetes in a population change 
when the new deﬁ nition of diabetes based on HbA1c is 
used compared with earlier deﬁ nitions based on blood 
glucose? Second, how does the new deﬁ nition of diabetes 
based on HbA1c compare with earlier deﬁ nitions in 
identifying previously undiagnosed people with diabetes, 
as measured by the sensitivity and speciﬁ city of the new 
deﬁ nition with respect to the previous ones? We further 
assessed whether sensitivity varied by the characteristics 
of the study population, because this possible variation is 
a source of concern about the generalisability of HbA1c as 
a diagnostic and surveillance measure.17,67–70
For the HbA1c-based deﬁ nition of diabetes, we used 
HbA1c of 6·5% or more, or history of diagnosis with 
diabetes or using insulin or oral hypoglycaemic drugs.11 
For deﬁ nitions based on blood glucose, we used either 
the American Diabetes Association deﬁ nition of FPG of 
7·0 mmol/L or more, or history of diagnosis with 
diabetes or using insulin or oral hypoglycaemic drugs 
(which is also used in the global monitoring framework 
for prevention and control of non-communicable 
diseases),12,18 or the WHO deﬁ nition of FPG of 
7·0 mmol/L or more, or 2hOGTT of 11·1 mmol/L or 
more, or history of diabetes or using insulin or oral 
hypoglycaemic drugs.9,10
Data sources
We used population-based data collated by the NCD Risk 
Factor Collaboration (NCD-RisC), a worldwide network 
of health researchers and practitioners who, together 
with WHO, have collated a large database of population-
based health examination surveys and epidemiological 
studies of cardiometabolic risk factors. All data sources 
were checked by at least two independent reviewers as 
being representative of a national, subnational, or 
community population, and for study quality indicators 
such as fasting duration and the protocol for OGTT. We 
excluded surveys that had not used a standard glucose 
load for OGTT. Within each survey, we included 
participants aged 18 years and older who were not 
pregnant and had fasted at least for 6 h before 
measurement as a part of the survey instructions. We 
excluded HbA1c data from before the year 2000 to 
minimise the use of non-standard assays.71 We also 
excluded surveys that had measured a biomarker only 
among participants with a high value of another—eg, 
studies in which FPG was only measured in participants 
with HbA1c above a prespeciﬁ ed value, because the 
relation between the two measurements might be 
Figure 1: Study and data inclusion
FPG=fasting plasma glucose. 2hOGTT=2-h oral glucose tolerance test. *The meta-analyses used inverse of variance as survey weights; sensitivity or speciﬁ city of either 0% or 100% would make the 
corresponding variance zero, and therefore the inverse of variance inﬁ nite. 
68 surveys (200 983 participants) with individual-level 
 data for at least two glucose biomarkers
68 surveys (190 516 participants)
51 surveys (143 651 participants) included in
meta-analyses of diagnostic sensitivity and specificity
of glucose biomarkers
27 surveys (86 312 participants) with individual-level 
  data for HbA1c and FPG
 9 surveys (27 482 participants) with individual-level 
  data for HbA1c, FPG, and 2hOGTT
 33 surveys (84 821 participants) with individual-level 
  data for FPG and 2hOGTT
10 467 participants excluded
 8148 aged <18 years or were pregnant 
 2319 had not fasted or had unacceptable 
  fasting duration (<6 or >24 h)
Exclusions
 11 surveys (29 381 participants) were follow-ups 
  of other studies included in the analysis
13 863 participants had diagnosed diabetes or were 
  taking diabetes drugs
140 participants had data for only HbA1c and
2hOGTT, but not FPG
 6 surveys (3481 participants) with undefinable 
  sensitivity (no undiagnosed diabetics) or with 
  either sensitivity or specificity of 0% or 100%*
29 surveys (148 498 participants) with summarised 
 prevalence data for at least two diabetes definitions
68 surveys (184 345 participants) with individual-level data 
29 surveys (148 498 participants) with summarised 
 prevalence data
96 surveys (331 288 participants) with data for at least 
       two diabetes definitions included in analysis of 
       diabetes prevalence
Exclusions
1 survey (154 participants) plus an 
 additional 1401 participants were in 
 age–sex groups with sample size <25
6171 particpants excluded
 3532 participants did not have data for 
  least two diabetes definitions
 2639 participants had missing 
  primary sampling unit, strata or 
  sample weight where complex 
  sample design existed
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diﬀ erent in this prescreened group compared with the 
whole sample. The appendix shows details of individual 
surveys.
We restricted the analysis of sensitivity and speciﬁ city 
to people without a history of diabetes diagnosis, because 
previous diagnosis and the use of drug treatments 
probably aﬀ ect the concentrations of biomarkers used to 
diagnose diabetes. History of diabetes diagnosis was 
established with survey-speciﬁ c questions, such as “have 
you ever been told by a doctor or other health professional 
that you have diabetes?” or the combination of “do you 
now have, or have you ever had diabetes?” and “were you 
told by a doctor that you had diabetes?”. We also excluded 
follow-up surveys of closed cohorts from the analysis of 
sensitivity and speciﬁ city because active surveillance 
within a cohort shifts participants from undiagnosed to 
diagnosed status at each follow-up, thus aﬀ ecting the 
composition of undiagnosed cases.
Statistical analysis
We calculated diabetes prevalence by sex and age group, 
taking into account complex survey design and survey 
sample weights when relevant. We excluded age–sex 
groups with fewer than 25 participants when calculating 
prevalence because the sampling error of estimated 
prevalence can bias the associations between prevalences 
based on diﬀ erent deﬁ nitions. Some surveys had 
measured HbA1c or FPG in all participants, but had not 
measured 2hOGTT among people with diagnosed 
diabetes. These previously diagnosed participants were 
included in calculation of diabetes prevalence because 
their exclusion would underestimate diabetes prevalence. 
Furthermore, some surveys measured 2hOGTT in only a 
subset of people without history of diabetes diagnosis, 
generally for logistical or cost reasons. Simply combining 
these participants with previously diagnosed participants 
might overestimate diabetes prevalence based on 
2hOGTT. To account for these missing measurements, 
and to avoid overestimation of diabetes prevalence, we 
recalculated the survey sample weights for these 
participants as the original sample weights divided by 
weighted proportion of non-diabetic participants with 
data. This approach is similar to that used in the US 
National Health and Nutrition Examination Survey for 
their 2hOGTT sample weights.72 A similar approach was 
taken in a few surveys that had measured HbA1c in all 
participants, but had not measured FPG among people 
diagnosed with diabetes.
We compared graphically the prevalences of diabetes 
using diﬀ erent deﬁ nitions. We also did regression 
analyses of the relation between diabetes deﬁ ned (1) on 
the basis of FPG-or-2hOGTT versus on the basis of FPG 
only and (2) on the basis of HbA1c versus on the basis of 
FPG. We did not do a regression for diabetes prevalence 
based on HbA1c versus prevalence based on FPG-or-
2hOGTT because very few surveys had data for both 
2hOGTT and HbA1c, leading to unstable regression 
coeﬃ  cients. We probit-transformed diabetes prevalence 
because it provided better ﬁ t to the data and it avoids 
predicting prevalences that are less than 0 or greater 
Figure 2: Prevalence of diabetes deﬁ ned by FPG-or-2hOGTT versus by FPG only
FPG-or-2hOGTT deﬁ nition was FPG 7·0 mmol/L or more, or 2hOGTT 11·1 mmol/L or more, or history of diabetes or 
using insulin or oral hypoglycaemic drugs. FPG only deﬁ nition was FPG 7·0 mmol/L or more, or history of diabetes or 
using insulin or oral hypoglycaemic drugs. Each point shows one age–sex group in one survey. Table 1 shows the 
relation summarised as regression coeﬃ  cients. FPG=fasting plasma glucose. 2hOGTT=2-h oral glucose tolerance test.
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Coeﬃ  cient (95% CI) p value Univariate 
R2*
Semipartial 
R2†
Intercept 0·135 (–0·020 to 0·290) 0·0872 NA NA
Probit-transformed prevalence of 
diabetes based on FPG
0·903 (0·880 to 0·927) <0·0001 0·963 0·368
Mean age of age–sex group (per 
10 years older)
0·048 (0·039 to 0·056) <0·0001 0·444 0·008
Study midyear (per one more 
recent year since 1976)
–0·001 (–0·002 to 0·000) 0·1643 0·003 <0·001
Natural logarithm of per person 
gross domestic product
–0·033 (–0·046 to –0·019) <0·0001 0·004 0·001
Mean BMI 0·000 (–0·004 to 0·004) 0·9057 0·092 <0·001
Study representativeness ·· ·· 0·021 0·001
National Reference ·· ·· ··
Subnational –0·031 (–0·070 to 0·008) 0·1141 ·· ··
Community –0·070 (–0·101 to –0·039) <0·0001 ·· ··
FPG=fasting plasma glucose. 2hOGTT=2-h oral glucose tolerance test. *Calculated by regressing against each 
independent variable alone; equals the square of the correlation coeﬃ  cient. †Shows how much R2 decreases if that 
independent variable is removed from the full model; the overall R2 for the model was 0·973. 
Table 1: Regression coeﬃ  cients for the relation between probit-transformed prevalence of diabetes 
based on FPG-or-2hOGTT versus diabetes based on FPG only
See Online for appendix
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than 1. We considered regression models with alternative 
covariates and speciﬁ cations, and chose the best model 
using the Bayesian information criterion, which measures 
the relative goodness of ﬁ t of a model; it rewards how well 
the model ﬁ ts the data but discourages overﬁ tting.73 The 
regressions included age (mean age of each age–sex 
group); the years over which each survey collected data (as 
the midyear of the period of data collection; appendix); 
national income (natural logarithm of per person gross 
domestic product) in the survey country and year; whether 
the study was representative of a national, subnational, or 
community population; and mean BMI for each age–sex 
group. Sex was excluded from the regressions on the basis 
of the Bayesian information criterion. The regression of 
diabetes prevalence based on HbA1c against diabetes 
prevalence based on FPG, for which there were more data, 
also included terms for geographical region as random 
eﬀ ects on the basis of Bayesian information criterion; 
these random eﬀ ects account for diﬀ erences in the 
relationship by region. Two regions consisted of high-
income countries, as in previous global analyses5,74—high-
income Asia Paciﬁ c (consisting of Japan, Singapore, and 
Coeﬃ  cient (95% CI) p value* Univariate R²† Semipartial R²‡
Intercept –1·761 (–2·229 to –1·266) <0·0001 NA NA
Probit-transformed prevalence of diabetes based on FPG 0·799 (0·763 to 0·835) <0·0001 0·915 0·075
Mean age of age–sex group (per 10 years older) 0·052 (0·042 to 0·062) <0·0001 0·601 0·011
Study midyear (per one more recent year since 2000) 0·012 (0·009 to 0·015) <0·0001 0·014 0·006
Natural logarithm of per person gross domestic product 0·076 (0·035 to 0·114) 0·0001 0·052 0·003
Mean BMI 0·018 (0·010 to 0·027) <0·0001 0·022 0·002
Study representativeness ·· ·· 0·013 0·004
National Reference ·· ·· ··
Subnational –0·004 (–0·047 to 0·040) 0·8758 ·· ··
Community 0·090 (0·060 to 0·119) <0·0001 ·· ··
The appendix shows regional random eﬀ ects. FPG=fasting plasma glucose. *p values using likelihood ratio test, which compares the likelihood of the models with and 
without the variable of interest.78 †Calculated by regressing against each independent variable alone, without the regional random eﬀ ect; equals the square of the correlation 
coeﬃ  cient. ‡Is the decrease of R² if one of the independent variables is removed from the full model; however, traditional R² is not clearly deﬁ ned for mixed-eﬀ ect models, we 
have used the conditional R² that describes the proportion of variance explained by both ﬁ xed and random factors.79 The overall conditional R² for the model was 0·949. 
Table 2: Regression coeﬃ  cients for the association between probit-transformed prevalence of diabetes based on HbA1c and probit-transformed 
prevalence based on FPG
Figure 3: Prevalence of diabetes deﬁ ned by HbA1c only versus prevalence deﬁ ned by (A) FPG only, and (B) FPG-or-2hOGTT
HbA1c deﬁ nition was HbA1c 6·5% or more, or history of diabetes, or using insulin or oral hypoglycaemic drugs. FPG only deﬁ nition was FPG 7·0 mmol/L or more, or 
history of diabetes or using insulin or oral hypoglycaemic drugs. FPG-or-2hOGTT deﬁ nition was FPG 7·0 mmol/L or more, or 2hOGTT 11·1 mmol/L or more, or history 
of diabetes or using insulin or oral hypoglycaemic drugs. Each point shows one age–sex group in one survey. Table 2 shows the relations summarised as regression 
coeﬃ  cients. FPG=fasting plasma glucose. 2hOGTT=2-h oral glucose tolerance test.
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South Korea) and high-income western countries 
(consisting of countries in Australasia, North America, 
and western Europe). The other countries were divided 
based on their geography into central and eastern Europe; 
central Asia, Middle East and north Africa; east and 
southeast Asia; south Asia; Latin America and the 
Caribbean; and sub-Saharan Africa.
We plotted the residuals of the regression models against 
the main independent variable (probit-transformed FPG-
based prevalence), and found no evidence of hetero-
scedasticity in the residuals. We also report the univariate 
and semipartial R² for each of the variables in the 
regression model. Univariate R² measures how much of 
the variance is explained by each independent variable. 
Semipartial R² measures the contribution of each variable 
to the total explained variance, conditional on the presence 
of the other model variables.75
We calculated sensitivity and speciﬁ city of diagnosis 
separately in each survey, and then pooled the sensitivities 
and speciﬁ cities across surveys with a random-eﬀ ects 
model.76 We examined the sources of heterogeneity in 
sensitivity and speciﬁ city with metaregressions and 
a-priori selected study characteristics: mean age, 
proportion of male participants, midyear of study data 
collection period; sample size; prevalence of undiagnosed 
diabetes in the survey; whether the survey was 
representative of a national, subnational, or community 
population; geographical region; national income in the 
survey country and year; and mean haemoglobin 
concentration in the survey country and year. We did the 
analyses with Stata (version 12.2) and R (version 3.0.3).
Role of the funding source
The funders had no role in study design, data collection, 
analysis, or interpretation, or writing of the report. SF, 
YL, and BZ had full access to all the data. ME was 
responsible for submitting the Article for publication.
Results
After exclusions, we included 96 population-based health 
examination surveys of 331 288 participants (ﬁ gure 1). 
46 surveys were from Australia, USA, and western Europe; 
18 from east and southeast Asia; ten from Latin America 
and the Caribbean; seven from Oceania; six from sub-
Saharan Africa; ﬁ ve from south Asia; three from the 
Middle East and north Africa; and one from central and 
eastern Europe. All 96 studies measured FPG; 47 also 
measured 2hOGTT and 63 measured HbA1c (appendix). 
14 of these studies measured all three biomarkers. All but 
three studies of the 47 studies used for comparing 
prevalence based on FPG alone versus based on FPG-or-
2hOGTT measured FPG in a laboratory; two of the 
remaining studies used a portable unit, and we did not 
have information for the remaining study. All studies 
measured 2hOGTT in a laboratory. All but one of the 
63 studies used for comparing glucose-based and 
HbA1c-based prevalences measured glucose in a laboratory; 
the remaining study measured FPG with a portable unit. 
An enzymatic method was used to measure FPG in 65 of 
the 92 studies that had measured FPG in a laboratory, but 
we had no information for the remaining 27 studies. In all 
63 studies, HbA1c was measured in a laboratory; in 40 of 
these studies, the measurements were done by 
chromatography or immunoassay. No information was 
available for the remaining 23. Such a dominance of 
laboratory-based measurements prevented us from 
assessing the role of measurement method as a source of 
variation because laboratory-based methods are equally 
acceptable, especially for glucose.77
Diabetes prevalence ranged from 0% in people younger 
than 40 years of age in some surveys to about 70% in 
Number 
of 
surveys
Sensitivity Speciﬁ city
(%; 95% CI) I² (%; 95% CI) I2
HbA1c vs FPG 27 52·82 (51·33–54·30) 97·6% 99·74 (99·71–99·78) 98·2%
HbA1c vs 2hOGTT 9 37·16 (35·05–39·28) 97·6% 99·84 (99·79–99·89) 97·3%
HbA1c vs FPG-or-2hOGTT 9 30·46 (28·66–32·25) 97·9% 99·69 (99·63–99·76) 98·0%
FPG vs 2hOGTT 33 54·42 (53·26–55·57) 96·9% 98·90 (98·83–98·97) 94·4%
The appendix shows detailed results of these meta-analyses. Diabetes was deﬁ ned as HbA1c ≥6·5%, FPG ≥7·0 mmol/L, 
and 2hOGTT ≥11·1 mmol/L. FPG=fasting plasma glucose. 2hOGTT=2-h oral glucose tolerance test. 
Table 3: Pooled sensitivity and speciﬁ city of diabetes diagnosis using diﬀ erent deﬁ nitions among 
participants without diagnosed diabetes
Mean diﬀ erence in 
sensitivity 
(percentage points; 
95% CI)
p value
Mean age (per 10 years older)  –4·1 (–12·7 to 4·5) 0·3361
Percent male participants (per 10% more male)  4·6 (–9·0 to 18·2) 0·4901
Study midyear (per one more recent year) 1·2 (–0·9 to 3·2) 0·2566
Region ·· 0·2097
High-income western countries Reference group ··
East, south, and southeast Asia 21·0 (–0·3 to 42·2) ··
Latin America and the Caribbean 8·5 (–17·9 to 34·9) ··
Sub-Saharan Africa  17·6 (–14·1 to 49·2) ··
Study representativeness ·· 0·0915
National Reference group ··
Subnational 1·7 (–28·6 to 31·9) ··
Community 21·4 (2·1 to 40·8) ··
Prevalence of undiagnosed diabetes (percentage point higher 
undiagnosed diabetes)
–0·7 (–4·0 to 2·6) 0·6780
Sample size (per 1000 participants without diagnosed diabetes) –1·6 (–4·6 to 1·4) 0·2730
Natural logarithm of per person gross domestic product –6·5 (–17·6 to 4·6) 0·2410
Mean haemoglobin (per g/L)* –2·0 (–4·1 to 0·2) 0·0677
We used a HbA1c deﬁ nition of 6·5% or more and a FPG deﬁ nition of 7·0 mmol/L or more. FPG=fasting plasma glucose. 
*Reliable mean haemoglobin data were available only for women of child-bearing age.82 The national mean for each 
country-year was used for both men and women; restricting the analysis to women led to similar results, with a mean 
diﬀ erence of –2·1 (–4·5 to 0·3, p=0·0929).
Table 4: Univariate metaregression coeﬃ  cients for sensitivity of HbA1c versus FPG in participants 
without diagnosed diabetes
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middle-aged and older adults in Nauru (ﬁ gure 2). 
Prevalence of diabetes based on FPG alone was lower 
than that based on FPG-or-2hOGTT, by 2–6 percentage 
points at diﬀ erent prevalence levels, although prevalences 
estimated using these two glucose-based measures were 
highly correlated (r=0·98; ﬁ gure 2). Tables 1 and 2 show 
results of the regression analyses. After accounting for 
prevalence based on FPG, prevalence based on FPG-or-
2hOGTT increased with age—ie, prevalence based on 
FPG-or-2hOGTT rose more sharply with age than did 
prevalence based on FPG only.65,80,81
HbA1c-based prevalences were lower than those based 
on FPG for 42·8% of age–sex–survey groups and higher 
in another 41·6%; in the other 15·6%, the two deﬁ nitions 
gave similar prevalences (ﬁ gure 3). In the regression 
analysis, prevalence based on HbA1c was on average 
slightly lower than prevalence based on FPG (table 2). The 
most important determinant of variation between these 
two prevalences was age, with some eﬀ ect from national 
income, mean BMI, year of survey, and whether the 
survey was representative of a national, subnational, or 
community population. After accounting for prevalence 
based on FPG, prevalence based on HbA1c increased with 
age, national income, mean BMI, and the year of survey. 
After accounting for prevalence based on FPG, HbA1c-
based prevalence was higher in south Asia than in other 
regions, and was lower in high-income regions than in 
other regions (appendix).
Diabetes deﬁ ned as HbA1c of 6·5% or more had a 
pooled sensitivity of 52·8% (95% CI 51·3–54·3) compared 
with a deﬁ nition of FPG of 7·0 mmol/L or more for 
diagnosing participants without a previous diagnosis of 
diabetes. This ﬁ nding suggests that 47·2% of participants 
without a previous diagnosis of diabetes who would be 
considered to have diabetes based on their FPG 
concentration would not be considered to have diabetes 
with an HbA1c test (table 3). The sensitivity of HbA1c varied 
substantially across studies (I² of 97·6%), ranging from 
13·0% to 93·2% (appendix pp 11–12). HbA1c had even 
lower sensitivity when compared with deﬁ ning diabetes 
based on FPG-or-2hOGTT (30·5%, 95% CI 28·7–32·3). 
None of the preselected study-level characteristics 
explained the heterogeneity in the sensitivity of HbA1c 
versus FPG (all p values >0·06; table 4). Pooled speciﬁ city 
of HbA1c was 99·74% (95% CI 99·71–99·78) relative to 
FPG and 99·69% (99·63–99·76) relative to FPG-or-
2hOGTT, suggesting few false positives compared with 
glucose-based deﬁ nitions.
Lowering the threshold for diabetes by HbA1c from 6·5% 
to 6·3% (a cutoﬀ  suggested by some studies49,50) increased 
sensitivity compared with the FPG-based deﬁ nition from 
52·8% to 64·3% while maintaining a high speciﬁ city at 
99·53%. Lowering it further to 6·1% increased sensitivity 
to 72·8% but the speciﬁ city would drop to 99·08%, 
resulting in more false positives. Follow-up studies are 
needed to establish how these cutoﬀ s predict complications 
and sequelae in newly diagnosed patients.83,84
Discussion
In this large international pooled analysis of population-
based health examination surveys, we found that the use of 
diﬀ erent biomarkers and deﬁ nitions for diabetes can lead 
to diﬀ erent estimates of population prevalence of diabetes, 
with the highest prevalence when diabetes is deﬁ ned on 
the basis of FPG-or-2hOGTT and the lowest when based 
on HbA1c alone. For example, at an FPG-based prevalence 
of 10%, similar to the age-standardised global prevalence 
of diabetes in adults aged 25 years and older in 2008,1 
prevalence based on FPG-or-2hOGTT would be about 13% 
according to the relation in ﬁ gure 2. The variation across 
studies in the relation between glucose-based and 
HbA1c-based prevalences was partly related to age, followed 
by national income, mean BMI, the year of survey, and 
whether the survey population was national, subnational, 
or from speciﬁ c communities. The reasons for additional 
regional eﬀ ects—higher HbA1c-based prevalence in south 
Asia and lower prevalence in high-income regions than in 
other regions after accounting for prevalence based on 
FPG—are unknown, but they might be a result of true 
physiological diﬀ erences; for example, related to red blood 
cell turnover (itself related to anaemia and iron status), 
which aﬀ ects HbA1c, or related to glucose dysregulation 
during fasting and non-fasting which are captured by 
HbA1c.85 Establishing these reasons requires multicentre 
studies with consistent methods and protocols and data for 
phenotypical factors that might aﬀ ect the relation between 
glucose and HbA1c. For now, they are unexplained 
empirical results that should be taken into account when 
using surveys from diﬀ erent regions.
Similarly, diﬀ erent deﬁ nitions identiﬁ ed diﬀ erent 
people without a previous diagnosis as having diabetes. 
Speciﬁ cally, use of an HbA1c-based deﬁ nition would not 
identify almost half of the undiagnosed cases that could 
be detected with a FPG test, and more than three-quarters 
of undiagnosed cases that would be detected by FPG and 
2hOGTT combined, but it would lead to few false 
positives compared with glucose-based deﬁ nitions. 
Inversely, using a glucose-based test alone would not 
identify some people who would be considered as having 
diabetes with HbA1c.
Our results, based on a large number of surveys from 
diﬀ erent regions, are consistent with previous smaller 
studies that compared diﬀ erent diabetes deﬁ nitions. 
Diabetes prevalence based on FPG-or-2hOGTT was 
higher than prevalence based on FPG alone by 18% in an 
analysis of 13 European cohorts and by 6% in an analysis 
of 11 Asian cohorts.63,64 A previous comparison of diabetes 
prevalence across six studies, including two analysed 
here, reported that diagnostic sensitivity for HbA1c 
compared with 2hOGTT ranged from 17% to 78%,67 
which is consistent with the results of our analysis. 
However, this study also found surprisingly low 
speciﬁ cities for HbA1c compared with ours.67 Other 
single-cohort studies also generally reported low but 
variable sensitivities and high speciﬁ cities for HbA1c 
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relative to blood glucose. Several studies86–89 assessed the 
optimal cutoﬀ  for HbA1c in diﬀ erent populations and all 
reported values lower than 6·5%, which is consistent 
with our ﬁ nding that lowering the threshold would 
increase sensitivity while preserving high speciﬁ city. One 
small study90 examined the eﬀ ect of anaemia on 
diagnostic accuracy of HbA1c and reported higher 
sensitivity (than with FPG) in patients with anaemia, 
which is consistent with our results.
Our analysis, which focused on questions that are 
relevant for population-based surveillance of diabetes and 
monitoring treatment coverage, has several strengths. We 
pooled data from a large number of population-based 
surveys from diﬀ erent world regions, thereby increasing 
both the precision of our estimates and their 
generalisability compared with analyses of one or a small 
number of cohorts. We used consistent eligibility and 
inclusion criteria, and assessed whether the surveys met 
these criteria. In particular, we only used surveys that had 
rigorous protocols for fasting duration and for OGTT. 
Furthermore, most surveys measured glucose and HbA1c 
in a laboratory. We also assessed the sources of 
heterogeneity in how diagnostic criteria compare across 
surveys, which could not be done in previous analyses 
because they included few surveys.
Our results should be interpreted with some limitations 
in mind. We had few studies from some regions 
including sub-Saharan Africa, south Asia, the Middle 
East and north Africa, and central and eastern Europe. 
 We analysed the surveys with consistent methods but 
surveys might have diﬀ ered in details such as the exact 
limit for fasting duration beyond the 6-h limit imposed 
by us. Because HbA1c measurement has changed over 
time,91–99 and to minimise the use of non-standard assays, 
we did not include any HbA1c data from before the year 
2000.71 Despite this exclusion, and the fact that all of our 
surveys had measured HbA1c in a laboratory, HbA1c 
measurements can vary between laboratories and 
instruments,100 about which we did not have complete 
data. For the same reason, we could not standardise the 
HbA1c data to account for diﬀ erent assays and instruments 
used in measurement. Nutritional status—especially 
iron deﬁ ciency—anaemia, malaria and other parasitic 
diseases, living at high altitudes, and high prevalence of 
haemoglobinopathies can aﬀ ect HbA1c,101 but could not be 
assessed as a source of heterogeneity beyond their eﬀ ects 
through mean haemoglobin concentration. Similarly, 
data for glucose can be aﬀ ected by unrecorded factors 
such as inaccurate information about fasting, ﬂ uctuations 
in diet and physical activity in days before measurement, 
and how samples were handled, including time between 
drawing blood and laboratory analysis and the type of 
tube used for collecting and storing blood. 
Although we assessed the role of geographical region, 
we did not have data for the ethnic composition of 
participants in each survey. By their nature, health 
examination surveys used for population-based 
surveillance use a single measurement for each 
participant, whereas diagnosis in a clinical setting might 
repeat the measurements based on the ﬁ rst test. The use 
of a single test is aﬀ ected by within-individual and even 
within-laboratory variation, and could lead to 
misclassiﬁ cation of some individuals.99 Finally, we did 
not have longitudinal follow-up data to assess sensitivity 
and speciﬁ city for diagnosis using one deﬁ nition (or one 
cutoﬀ  value of HbA1c) compared to another or for 
development of diabetes complications and sequelae that 
contribute the bulk of the public health burden of 
diabetes. Such data are not available in population-based 
surveys because surveys are typically cross-sectional.
There is no gold standard deﬁ nition that captures the 
phenotypic complexity of diabetes and the risk of its 
microvascular and macrovascular complications, 
although 2hOGTT is often treated as the most reliable 
test.15,102,103 In clinical practice, physicians follow an 
analytical process to diagnose diabetes, in which diﬀ erent 
sequences of glucose biomarkers are used depending on 
factors such as a patient’s age and symptoms; those with 
high levels of one biomarker (eg, HbA1c) might be asked 
to have additional measurements of the same or a 
diﬀ erent biomarker, and be monitored over time to 
decide on the best course of treatment. The process 
might vary from patient to patient to account for their 
unique characteristics, and might further vary from 
physician to physician based on available infrastructure 
and medical resources. In surveillance using population-
based surveys, which provides evidence for policies and 
programmes related to whole populations, repeated 
measurements are virtually impossible. Therefore, 
considerations about diabetes deﬁ nition and diagnosis 
are diﬀ erent from those of clinical practice, and the 
emphasis is on comparability of deﬁ nitions over time 
and across populations. Our results provide much 
needed empirical evidence for planning global 
surveillance of diabetes and coverage of its interventions. 
Speciﬁ cally, despite its relative ease of use, using HbA1c 
alone in health surveys might miss some previously 
undiagnosed people who would be considered as having 
diabetes using a glucose-based test, and thus could 
beneﬁ t from lifestyle and treatment interventions. Even 
so, 2hOGTT is diﬃ  cult to measure even in a clinical 
setting, let alone in population-based surveys. Of 493 
worldwide population-based diabetes data sources 
between 1975 and 2014 in the NCD-RisC databases, 448 
had measured FPG but only 59 had measured 2hOGTT; 
33% of surveys before 1990 had 2hOGTT and only 11% 
did after 1990. Therefore, a strategy for consistent and 
comparable surveillance is to use FPG in population-
based surveys, be it national or multicountry survey 
programmes such as the WHO STEPS surveys, and 
deﬁ ne diabetes based on FPG. Data such as those in 
ﬁ gure 2 and table 1 can then be used to relate prevalences 
based on FPG to those based on FPG-or-2hOGTT. The 
use of HbA1c in surveillance requires further 
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consideration of how it predicts and helps prevent 
diabetes complications and sequelae. When HbA1c is 
used, FPG should ideally also be measured in a 
subsample of participants to provide information about 
how the two tests relate.
Contributors
GD and ME designed the study and oversaw research. Members of the 
Country and Regional Data Group collected and reanalysed data, and 
checked pooled data for accuracy of information about their study and 
other studies in their country. Members of the Pooled Analysis and 
Writing Group collated data, checked all data sources in consultation with 
the Country and Regional Data Group, analysed pooled data, and prepared 
results. GD and ME wrote the ﬁ rst draft of the report with input from 
other members of Pooled Analysis and Writing Group. Members of 
Country and Regional Data Group commented on draft report.
NCD Risk Factor Collaboration (NCD-RisC)
Pooled Analysis and Writing (*equal contribution; listed alphabetically)—
Goodarz Danaei (Harvard T H Chan School of Public Health, USA)*; 
Saman Fahimi (Harvard T H Chan School of Public Health, USA)*; 
Yuan Lu (Harvard T H Chan School of Public Health, USA)*; Bin Zhou 
(Imperial College London, UK)*; Kaveh Hajifathalian (Harvard T H Chan 
School of Public Health, USA); Mariachiara Di Cesare (Imperial College 
London, UK); Wei-Cheng Lo (National Taiwan University, Taiwan); 
Barbara Reis-Santos (Universidade Federal de Pelotas, Brazil); 
Melanie J Cowan (World Health Organization, Switzerland); 
Jonathan E Shaw (Baker IDI Heart and Diabetes Institute, Australia); 
James Bentham (Imperial College London, UK); John K Lin (University of 
California San Francisco, USA); Honor Bixby (Imperial College London, 
UK); Dianna Magliano (Baker IDI Heart and Diabetes Institute, Australia); 
Pascal Bovet (University of Lausanne, Switzerland; Ministry of Health, 
Seychelles); J Jaime Miranda (Universidad Peruana Cayetano Heredia, 
Peru); Young-Ho Khang (Seoul National University, South Korea); 
Gretchen A Stevens (World Health Organization, Switzerland); 
Leanne M Riley (World Health Organization, Switzerland); 
Mohammed K Ali (Emory University, USA); Majid Ezzati (Imperial 
College London, UK).
Country and Regional Data (*equal contribution; listed alphabetically)—
Ziad A Abdeen (Al-Quds University, Palestine)*; Khalid Abdul Kadir 
(Monash University Malaysia, Malaysia)*; Niveen M Abu-Rmeileh 
(Birzeit University, Palestine)*; Benjamin Acosta-Cazares (Instituto 
Mexicano del Seguro Social, Mexico)*; Wichai Aekplakorn (Mahidol 
University, Thailand)*; Carlos A Aguilar-Salinas (Instituto Nacional de 
Ciencias Médicas y Nutricion, Mexico)*; Alireza Ahmadvand (Tehran 
University of Medical Sciences, Iran)*; Mohannad Al Nsour (Eastern 
Mediterranean Public Health Network, Jordan)*; Ala’a Alkerwi 
(Luxembourg Health Institute, Luxembourg)*; Philippe Amouyel (Lille 
University and Hospital, France)*; Lars Bo Andersen (University of 
Southern Denmark, Denmark)*; Sigmund A Anderssen (Norwegian 
School of Sport Sciences, Norway)*; Dolores S Andrade (Universidad de 
Cuenca, Ecuador)*; Ranjit Mohan Anjana (Madras Diabetes Research 
Foundation, India)*; Hajer Aounallah-Skhiri (National Institute of Public 
Health, Tunisia)*; Tahir Aris (Ministry of Health Malaysia, Malaysia)*; 
Nimmathota Arlappa (Indian Council of Medical Research, India)*; 
Dominique Arveiler (Strasbourg University and Hospital, France)*; 
Fel ix K Assah (Health of Populations in Transition Research Group, 
Cameroon)*; Mária Avdicová (Regional Authority of Public Health, 
Banska Bystrica, Slovakia)*; Nagalla Balakrishna (Indian Council of 
Medical Research, India)*; Piotr Bandosz (Medical University of Gdansk, 
Poland)*; Carlo M Barbagallo (University of Palermo, Italy)*; 
Alberto Barceló (Pan American Health Organization, USA)*; 
Anwar M Batieha (Jordan University of Science and Technology, 
Jordan)*; Louise A Baur (University of Sydney, Australia)*; 
Habiba Ben Romdhane (University Tunis El Manar, Tunisia)*; 
Antonio Bernabe-Ortiz (Universidad Peruana Cayetano Heredia, Peru)*; 
Santosh K Bhargava (Sunder Lal Jain Hospital, India)*; Yufang Bi 
(Shanghai Jiao-Tong University School of Medicine, China)*; 
Peter Bjerregaard (University of Southern Denmark, Denmark; 
University of Greenland, Greenland)*; Cecilia Björkelund (University of 
Gothenburg, Sweden)*; Margaret Blake (NatCen Social Research, UK)*; 
Anneke Blokstra (National Institute for Public Health and the 
Environment, Netherlands)*; Simona Bo (University of Turin, Italy)*; 
Bernhard O Boehm (Nanyang Technological University, Singapore)*; 
Carlos P Boissonnet (Centro de Educación Médica e Investigaciones 
Clínicas, Argentina)*; Pascal Bovet (University of Lausanne, Switzerland; 
Ministry of Health, Seychelles)*; Imperia Brajkovich (Universidad 
Central de Venezuela, Venezuela)*; Juergen Breckenkamp (Bielefeld 
University, Germany)*; Lizzy M Brewster (University of Amsterdam, 
Netherlands)*; Garry R Brian (The Fred Hollows Foundation New 
Zealand, New Zealand)*; Graziella Bruno (University of Turin, Italy)*; 
Anna Bugge (University of Southern Denmark, Denmark)*; 
Antonio Cabrera de León (Canarian Health Service, Spain)*; Gunay Can 
(Istanbul University, Turkey)*; Ana Paula C Cândido (Universidade 
Federal de Juiz de Fora, Brazil)*; Vincenzo Capuano (Reparto di 
Cardiologia ed UTIC di Mercato S., Italy)*; Maria J Carvalho (University 
of Porto, Portugal)*; Felipe F Casanueva (Santiago de Compostela 
University, Spain)*; Carmelo A Caserta (Associazione Calabrese di 
Epatologia, Italy)*; Katia Castetbon (French Institute for Health 
Surveillance, France)*; Snehalatha Chamukuttan (India Diabetes 
Research Foundation, India)*; Nishi Chaturvedi (University College 
London, UK)*; Chien-Jen Chen (Academia Sinica, Taiwan)*; 
Fangfang Chen (Capital Institute of Pediatrics, China)*; Shuohua Chen 
(Kailuan General Hospital, China)*; Ching-Yu Cheng (Duke-NUS 
Graduate Medical School, Singapore)*; Angela Chetrit (The Gertner 
Institute for Epidemiology and Health Policy Research, Israel)*; 
Shu-Ti Chiou (Ministry of Health and Welfare, Taiwan)*; Yumi Cho 
(Korea Centers for Disease Control and Prevention, South Korea)*; 
Jerzy Chudek (Medical University of Silesia, Poland)*; Renata Cifkova 
(Charles University in Prague, Czech Republic)*; Frank Claessens 
(Katholieke Universiteit Leuven, Belgium)*; Hans Concin (Agency for 
Preventive and Social Medicine, Austria)*; Cyrus Cooper (University of 
Southampton, UK)*; Rachel Cooper (University College London, UK)*; 
Simona Costanzo (IRCCS Istituto Neurologico Mediterraneo Neuromed, 
Italy)*; Dominique Cottel (Institut Pasteur de Lille, France)*; 
Chris Cowell (Westmead University of Sydney, Australia)*; 
Ana B Crujeiras (CIBERobn, Spain)*; Graziella D’Arrigo (National 
Research Council, Italy)*; Jean Dallongeville (Institut Pasteur de Lille, 
France)*; Rachel Dankner (The Gertner Institute for Epidemiology and 
Health Policy Research, Israel)*; Luc Dauchet (Lille University Hospital, 
France)*; Giovanni de Gaetano (IRCCS Istituto Neurologico 
Mediterraneo Neuromed, Italy)*; Stefaan De Henauw (Ghent University, 
Belgium)*; Mohan Deepa (Madras Diabetes Research Foundation, 
India)*; Abbas Dehghan (University Medical Center Rotterdam, 
Netherlands)*; Klodian Dhana (University Medical Center Rotterdam, 
Netherlands)*; Augusto F Di Castelnuovo (IRCCS Istituto Neurologico 
Mediterraneo Neuromed, Italy)*; Shirin Djalalinia (Tehran University of 
Medical Sciences, Iran)*; Kouamelan Doua (Ministère de la Santé et de la 
Lutte contre le Sida, Côte d’Ivoire)*; Wojciech Drygas (The Cardinal 
Wyszynski Institute of Cardiology, Poland)*; Yong Du (Robert Koch 
Institute, Germany)*; Eruke E Egbagbe (University of Benin College of 
Medical Sciences, Nigeria)*; Robert Eggertsen (University of 
Gothenburg, Sweden)*; Jalila El Ati (National Institute of Nutrition and 
Food Technology, Tunisia)*; Roberto Elosua (Institut Hospital del Mar 
d’Investigacions Mèdiques, Spain)*; Rajiv T Erasmus (University of 
Stellenbosch, South Africa)*; Cihangir Erem (Karadeniz Technical 
University, Turkey)*; Gul Ergor (Dokuz Eylul University, Turkey)*; 
Louise Eriksen (University of Southern Denmark, Denmark)*; 
Jorge Escobedo-de la Peña (Instituto Mexicano del Seguro Social, 
Mexico)*; Caroline H Fall (MRC Lifecourse Epidemiology Unit, UK)*; 
Farshad Farzadfar (Tehran University of Medical Sciences, Iran)*; 
Francisco J Felix-Redondo (Centro de Salud Villanueva Norte, Spain)*; 
Trevor S Ferguson (The University of the West Indies, Jamaica)*; 
Daniel Fernández-Bergés (Hospital Don Benito-Villanueva de la Serena, 
Spain)*; Marika Ferrari (National Research Institute on Food and 
Nutrition, Italy)*; Catterina Ferreccio (Pontiﬁ cia Universidad Católica de 
Chile, Chile)*; Joseph D Finn (University of Manchester, UK)*; 
Bernhard Föger (Agency for Preventive and Social Medicine, Austria)*; 
Leng Huat Foo (Universiti Sains Malaysia, Malaysia)*; Heba M Fouad 
(World Health Organization Regional Oﬃ  ce for the Eastern 
Mediterranean, Egypt)*; Damian K Francis (The University of the West 
Indies, Jamaica)*; Maria do Carmo Franco (Federal University of São 
Articles
www.thelancet.com/diabetes-endocrinology   Vol 3   August 2015 633
Paulo, Brazil)*; Oscar H Franco (University Medical Center Rotterdam, 
Netherlands)*; Guillermo Frontera (Hospital Universitario Son Espases, 
Spain)*; Takuro Furusawa (Kyoto University, Japan)*; Zbigniew Gaciong 
(Medical University of Warsaw, Poland)*; Andrzej Galbarczyk 
(Jagiellonian University Medical College, Poland)*; Sarah P Garnett 
(University of Sydney, Australia)*; Jean-Michel Gaspoz (Geneva 
University Hospitals, Switzerland)*; Magda Gasull (CIBER en 
Epidemiología y Salud Pública, Spain)*; Louise Gates (Australian Bureau 
of Statistics, Australia)*; Johanna M Geleijnse (Wageningen University, 
Netherlands)*; Anoosheh Ghasemain (Tehran University of Medical 
Sciences, Iran)*; Simona Giampaoli (Istituto Superiore di Sanita, Italy)*; 
Francesco Gianfagna (University of Insubria, Italy)*; 
Jonathan Giovannelli (Lille University Hospital, France)*; 
Marcela Gonzalez Gross (Universidad Politécnica de Madrid, Spain)*; 
Juan P González Rivas (The Andes Clinic of Cardio-Metabolic Studies, 
Venezuela)*; Mariano Bonet Gorbea (National Institute of Hygiene, 
Epidemiology and Microbiology, Cuba)*; Frederic Gottrand (Université 
de Lille 2, France)*; Janet F Grant (The University of Adelaide, 
Australia)*; Tomasz Grodzicki (Jagiellonian University Medical College, 
Poland)*; Anders Grøntved (University of Southern Denmark, 
Denmark)*; Grabriella Gruden (University of Turin, Italy)*; 
Dongfeng Gu (National Center of Cardiovascular Diseases, China)*; 
Ong Peng Guan (Singapore Eye Research Institute, Singapore)*; 
Ramiro Guerrero (Universidad Icesi, Colombia)*; Idris Guessous 
(Geneva University Hospitals, Switzerland)*; Andre L Guimaraes (State 
University of Montes Claros, Brazil)*; Laura Gutierrez (Institute for 
Clinical Eﬀ ectiveness and Health Policy, Argentina)*; Rebecca Hardy 
(University College London, UK)*; Rachakulla Hari Kumar (Indian 
Council of Medical Research, India)*; Jiang He (Tulane University, 
USA)*; Christin Heidemann (Robert Koch Institute, Germany)*; 
Ilpo Tapani Hihtaniemi (Imperial College London, UK)*; Sai Yin Ho 
(University of Hong Kong, China)*; Suzanne C Ho (The Chinese 
University of Hong Kong, China)*; Albert Hofman (University Medical 
Center Rotterdam, Netherlands)*; Andrea R V Russo Horimoto (Heart 
Institute, Brazil)*; Claudia M Hormiga (Fundación Oftalmológica de 
Santander, Colombia)*; Bernardo L Horta (Universidade Federal de 
Pelotas, Brazil)*; Leila Houti (University of Oran 1, Algeria)*; 
Abdullatif S Hussieni (Birzeit University, Palestine)*; Inge Huybrechts 
(International Agency for Research on Cancer, France)*; Nahla Hwalla 
(American University of Beirut, Lebanon)*; Licia Iacoviello (IRCCS 
Istituto Neurologico Mediterraneo Neuromed, Italy)*; Anna G Iannone 
(Reparto di Cardiologia ed UTIC di Mercato S., Italy)*; 
Mohsen M Ibrahim (Cairo University, Egypt)*; Nayu Ikeda (National 
Institute of Health and Nutrition, Japan)*; M Arfan Ikram (University 
Medical Center Rotterdam, Netherlands)*; Vilma E Irazola (Institute for 
Clinical Eﬀ ectiveness and Health Policy, Argentina)*; Muhammad Islam 
(Aga Khan University, Pakistan)*; Masanori Iwasaki (Niigata University, 
Japan)*; Jeremy M Jacobs (Hadassah University Medical Center, Israel)*; 
Tazeen Jafar (Duke-NUS Graduate Medical School, Singapore)*; 
Grazyna Jasienska (Jagiellonian University Medical College, Poland)*; 
Chao Qiang Jiang (University of Hong Kong, China)*; Jost B Jonas 
(Ruprecht-Karls-University of Heidelberg, Germany)*; Pradeep Joshi 
(World Health Organization Country Oﬃ  ce, India)*; Anthony Kafatos 
(University of Crete, Greece)*; Ofra Kalter-Leibovici (The Gertner 
Institute for Epidemiology and Health Policy Research, Israel)*; 
Amir Kasaeian (Tehran University of Medical Sciences, Iran)*; 
Joanne Katz (Johns Hopkins Bloomberg School of Public Health, USA)*; 
Prabhdeep Kaur (National Institute of Epidemiology, India)*; 
Maryam Kavousi (University Medical Center Rotterdam, Netherlands)*; 
Roya Kelishadi (Isfahan University of Medical Sciences, Iran)*; 
Andre P Kengne (South African Medical Research Council, South 
Africa)*; Mathilde Kersting (Research Institute of Child Nutrition, 
Germany)*; Yousef Saleh Khader (Jordan University of Science and 
Technology, Jordan)*; Young-Ho Khang (Seoul National University, South 
Korea)*; Stefan Kiechl (Medical University Innsbruck, Austria)*; 
Jeongseon Kim (National Cancer Center, South Korea)*; Yutaka Kiyohara 
(Kyushu University, Japan)*; Patrick Kolsteren (Institute of Tropical 
Medicine, Belgium)*; Paul Korrovits (Tartu University Clinics, Estonia)*; 
Seppo Koskinen (National Institute for Health and Welfare, Finland)*; 
Wolfgang Kratzer (University Hospital Ulm, Germany)*; Daan Kromhout 
(Wageningen University, Netherlands)*; Krzysztof Kula (Medical 
University of Łodz, Poland)*; Pawel Kurjata (The Cardinal Wyszynski 
Institute of Cardiology, Poland)*; Catherine Kyobutungi (African 
Population and Health Research Center, Kenya)*; Carl Lachat (Ghent 
University, Belgium)*; Youcef Laid (National Institute of Public Health, 
Algeria)*; Tai Hing Lam (University of Hong Kong, China)*; 
Orlando Landrove (Ministerio de Salud Pública, Cuba)*; Vera Lanska 
(Institute for Clinical and Experimental Medicine Prague, Czech 
Republic)*; Georg Lappas (Sahlgrenska Academy, Sweden)*; 
Avula Laxmaiah (Indian Council of Medical Research, India)*; 
Catherine Leclercq (Food and Agriculture Organization, Italy)*; 
Jeannette Lee (National University of Singapore, Singapore)*; 
Jeonghee Lee (National Cancer Center, South Korea)*; Terho Lehtimäki 
(Tampere University Hospital, Finland)*; Rampal Lekhraj (Universiti 
Putra Malaysia, Malaysia)*; Luz M León-Muñoz (Universidad Autónoma 
de Madrid, Spain)*; Yanping Li (Harvard T H Chan School of Public 
Health, USA)*; Wei-Yen Lim (National University of Singapore, 
Singapore)*; M Fernanda Lima-Costa (Oswaldo Cruz Foundation Rene 
Rachou Research Institute, Brazil)*; Hsien-Ho Lin (National Taiwan 
University, Taiwan)*; Xu Lin (University of Chinese Academy of 
Sciences, China)*; Lauren Lissner (University of Gothenburg, Sweden)*; 
Roberto Lorbeer (University Medicine Greifswald, Germany)*; 
José Eugenio Lozano (Consejería de Sanidad Junta de Castilla y León, 
Spain)*; Annamari Lundqvist (National Institute for Health and Welfare, 
Finland)*; Per Lytsy (University of Uppsala, Sweden)*; Guansheng Ma 
(Peking University, China)*; George L L Machado-Coelho (Universidade 
Federal de Ouro Preto, Brazil)*; Suka Machi (The Jikei University School 
of Medicine, Japan)*; Stefania Maggi (National Research Council, Italy)*; 
Dianna Magliano (Baker IDI Heart and Diabetes Institute, Australia)*; 
Marcia Makdisse (Hospital Israelita Albert Einstein, Brazil)*; 
Kodavanti Mallikharjuna Rao (Indian Council of Medical Research, 
India)*; Yannis Manios (Harokopio University of Athens, Greece)*; 
Enzo Manzato (University of Padova, Italy)*; Paula Margozzini (Pontiﬁ cia 
Universidad Católica de Chile, Chile)*; Pedro Marques-Vidal (Lausanne 
University Hospital, Switzerland)*; Reynaldo Martorell (Emory 
University, USA)*; Shariq R Masoodi (Sher-i-Kashmir Institute of 
Medical Sciences, India)*; Tandi E Matsha (Cape Peninsula University of 
Technology, South Africa)*; Jean Claude N Mbanya (University of 
Yaoundé 1, Cameroon)*; Shelly R McFarlane (The University of the West 
Indies, Jamaica)*; Stephen T McGarvey (Brown University, USA)*; 
Stela McLachlan (University of Edinburgh, UK)*; Breige A McNulty 
(University College Dublin, Ireland)*; Sounnia Mediene-Benchekor 
(University of Oran 1, Algeria)*; Aline Meirhaeghe (INSERM, France)*; 
Ana Maria B Menezes (Universidade Federal de Pelotas, Brazil)*; 
Shahin Merat (Tehran University of Medical Sciences, Iran)*; 
Indrapal I Meshram (Indian Council of Medical Research, India)*; Jie Mi 
(Capital Institute of Pediatrics, China)*; Juan Francisco Miquel (Pontiﬁ cia 
Universidad Católica de Chile, Chile)*; J Jaime Miranda (Universidad 
Peruana Cayetano Heredia, Peru)*; Mostafa K Mohamed (Ain Shams 
University, Egypt)*; Kazem Mohammad (Tehran University of Medical 
Sciences, Iran)*; Viswanathan Mohan (Madras Diabetes Research 
Foundation, India)*; Muhammad Fadhli Mohd Yusoﬀ  (Ministry of 
Health Malaysia, Malaysia)*; Niels C Møller (University of Southern 
Denmark, Denmark)*; Denes Molnar (University of Pécs, Hungary)*; 
Charles K Mondo (Mulago Hospital, Uganda)*; Luis A Moreno 
(Universidad de Zaragoza, Spain)*; Karen Morgan (PU-RCSI School of 
Medicine, Malaysia)*; George Moschonis (Harokopio University of 
Athens, Greece)*; Malgorzata Mossakowska (International Institute of 
Molecular and Cell Biology, Poland)*; Aya Mostafa (Ain Shams 
University, Egypt)*; Jorge Mota (University of Porto, Portugal)*; 
Maria L Muiesan (University of Brescia, Italy)*; Martina Müller-Nurasyid 
(Helmholtz Zentrum München, Germany)*; Jaakko Mursu (University of 
Eastern Finland, Finland)*; Gabriele Nagel (University of Ulm, 
Germany)*; Jana Námešná (Regional Authority of Public Health, Banska 
Bystrica, Slovakia)*; Ei Ei K Nang (National University of Singapore, 
Singapore)*; Vinay B Nangia (Suraj Eye Institute, India)*; 
Eva Maria Navarrete-Muñoz (CIBER de Epidemiología y Salud Pública, 
Spain)*; Ndeye Coumba Ndiaye (INSERM, France)*; Flavio Nervi 
(Pontiﬁ cia Universidad Católica de Chile, Chile)*; Nguyen D Nguyen 
(University of Pharmacy and Medicine of Ho Chi Minh City, Vietnam)*; 
Ramﬁ s E Nieto-Martínez (Universidad Centro-Occidental Lisandro 
Alvarado, Venezuela)*; Guang Ning (Shanghai Jiao-Tong University 
Articles
634 www.thelancet.com/diabetes-endocrinology   Vol 3   August 2015
School of Medicine, China)*; Toshiharu Ninomiya (Kyushu University, 
Japan)*; Marianna Noale (National Research Council, Italy)*; 
Davide Noto (University of Palermo, Italy)*; Angélica M Ochoa-Avilés 
(Universidad de Cuenca, Ecuador)*; Kyungwon Oh (Korea Centers for 
Disease Control and Prevention, South Korea)*; Altan Onat (Istanbul 
University, Turkey)*; Clive Osmond (MRC Lifecourse Epidemiology Unit, 
UK)*; Johanna A Otero (Fundación Oftalmológica de Santander, 
Colombia)*; Luigi Palmieri (Istituto Superiore di Sanita, Italy)*; 
Songhomitra Panda-Jonas (Ruprecht-Karls-University of Heidelberg, 
Germany)*; Francesco Panza (Unversity of Bari, Italy)*; 
Mahboubeh Parsaeian (Tehran University of Medical Sciences, Iran)*; 
Sergio Viana Peixoto (Oswaldo Cruz Foundation Rene Rachou Research 
Institute, Brazil)*; Alexandre C Pereira (Heart Institute, Brazil)*; 
Annette Peters (Helmholtz Zentrum München, Germany)*; 
Niloofar Peykari (Tehran University of Medical Sciences, Iran)*; 
Aida Pilav (Federal Ministry of Health, Bosnia and Herzegovina)*; 
Freda Pitakaka (University of New South Wales, Australia)*; 
Aleksandra Piwonska (The Cardinal Wyszynski Institute of Cardiology, 
Poland)*; Jerzy Piwonski (The Cardinal Wyszynski Institute of 
Cardiology, Poland)*; Pedro Plans-Rubió (Public Health Agency of 
Catalonia, Spain)*; Miquel Porta (Hospital del Mar Medical Research 
Institute-IMIM, Spain)*; Marileen L P Portegies (University Medical 
Center Rotterdam, Netherlands)*; Hossein Poustchi (Tehran University 
of Medical Sciences, Iran)*; Rajendra Pradeepa (Madras Diabetes 
Research Foundation, India)*; Jacqueline F Price (University of 
Edinburgh, UK)*; Margus Punab (Tartu University Clinics, Estonia)*; 
Radwan F Qasrawi (Al-Quds University, Palestine)*; Mostafa Qorbani 
(Alborz University of Medical Sciences, Iran)*; Olli Raitakari (University 
of Turku, Finland)*; Sudha Ramachandra Rao (National Institute of 
Epidemiology, India)*; Ambady Ramachandran (India Diabetes Research 
Foundation, India)*; Rafel Ramos (Institut Universitari d’Investigació en 
Atenció Primària Jordi Gol, Spain)*; Sanjay Rampal (University of 
Malaya, Malaysia)*; Wolfgang Rathmann (German Diabetes Center, 
Germany)*; Josep Redon (University of Valencia, Spain)*; 
Paul Ferdinand M Reganit (University of the Philippines, Philippines)*; 
Fernando Rigo (Health Center San Agustin, Spain)*; Sian M Robinson 
(University of Southampton, UK)*; Cynthia Robitaille (Public Health 
Agency of Canada, Canada)*; Laura A Rodríguez (Universidad Industrial 
de Santander, Colombia)*; Fernando Rodríguez-Artalejo (Universidad 
Autónoma de Madrid, Spain)*; María del Cristo Rodriguez-Perez 
(Canarian Health Service, Spain)*; Rosalba Rojas-Martinez (Instituto 
Nacional de Salud Pública, Mexico)*; Dora Romaguera (Centre for 
Research in Environmental Epidemiology, Spain)*; Annika Rosengren 
(Sahlgrenska Academy, Sweden)*; Adolfo Rubinstein (Institute for 
Clinical Eﬀ ectiveness and Health Policy, Argentina)*; Ornelas Rui 
(University of Madeira, Portugal)*; Blanca Sandra Ruiz-Betancourt 
(Instituto Mexicano del Seguro Social, Mexico)*; Marcin Rutkowski 
(Medical University of Gdansk, Poland)*; Charumathi Sabanayagam 
(Singapore Eye Research Institute, Singapore)*; Harshpal S Sachdev 
(Sitaram Bhartia Institute of Science and Research, India)*; Olfa Saidi 
(University Tunis El Manar, Tunisia)*; Sibel Sakarya (Marmara 
University, Turkey)*; Benoit Salanave (French Institute for Health 
Surveillance, France)*; Jukka T Salonen (University of Helsinki, 
Finland)*; Massimo Salvetti (University of Brescia, Italy)*; 
Jose Sánchez-Abanto (National Institute of Health, Peru)*; Renata Nunes 
dos Santos (University of São Paulo, Brazil)*; Rute Santos (University of 
Porto, Portugal)*; Luis B Sardinha (Universidade de Lisboa, Portugal)*; 
Marcia Scazufca (University of São Paulo, Brazil)*; 
Herman Schargrodsky (Hospital Italiano de Buenos Aires, Argentina)*; 
Christa Scheidt-Nave (Robert Koch Institute, Germany)*; 
Jonathan E Shaw (Baker IDI Heart and Diabetes Institute, Australia)*; 
Kenji Shibuya (The University of Tokyo, Japan)*; Youchan Shin 
(Singapore Eye Research Institute, Singapore)*; Rahman Shiri (Finnish 
Institute of Occupational Health, Finland)*; Rosalynn Siantar (Singapore 
Eye Research Institute, Singapore)*; Abla M Sibai (American University 
of Beirut, Lebanon)*; Mary Simon (India Diabetes Research Foundation, 
India)*; Judith Simons (St Vincent’s Hospital, Australia)*; Leon A 
Simons (University of New South Wales, Australia)*; Michael Sjostrom 
(Karolinska Institute, Sweden)*; Jolanta Slowikowska-Hilczer (Medical 
University of Łodz, Poland)*; Przemyslaw Slusarczyk (International 
Institute of Molecular and Cell Biology, Poland)*; Liam Smeeth (London 
School of Hygiene & Tropical Medicine, UK)*; Marieke B Snijder 
(University of Amsterdam, Netherlands)*; Vincenzo Solfrizzi (University 
of Bari, Italy)*; Emily Sonestedt (Lund University, Sweden)*; Aicha 
Soumare (University of Bordeaux, France)*; Jan A Staessen (University 
of Leuven, Belgium)*; Jostein Steene-Johannessen (Norwegian School of 
Sport Sciences, Norway)*; Peter Stehle (Bonn University, Germany)*; 
Aryeh D Stein (Emory University, USA)*; Jochanan Stessman (Hadassah 
University Medical Center, Israel)*; Doris Stöckl (Helmholtz Zentrum 
München, Germany)*; Jakub Stokwiszewski (National Institute of 
Hygiene, Poland)*; Maria Wany Strufaldi (Federal University of São 
Paulo, Brazil)*; Chien-An Sun (Fu Jen Catholic University, Taiwan)*; 
Johan Sundström (Uppsala University, Sweden)*; 
Paibul Suriyawongpaisal (Mahidol University, Thailand)*; Rody G Sy 
(University of the Philippines, Philippines)*; E Shyong Tai (National 
University of Singapore, Singapore)*; Mohammed Tarawneh (Ministry of 
Health, Jordan)*; Carolina B Tarqui-Mamani (National Institute of 
Health, Peru)*; Lutgarde Thijs (University of Leuven, Belgium)*; 
Janne S Tolstrup (University of Southern Denmark, Denmark)*; 
Murat Topbas (Karadeniz Technical University, Turkey)*; Maties Torrent 
(Area de Salut de Menorca, Spain)*; Pierre Traissac (Institut de 
Recherche pour le Développement, France)*; Oanh T H Trinh (University 
of Pharmacy and Medicine of Ho Chi Minh City, Vietnam)*; 
Marshall K Tulloch-Reid (The University of the West Indies, Jamaica)*; 
Tomi-Pekka Tuomainen (University of Eastern Finland, Finland)*; 
Maria L Turley (Ministry of Health, New Zealand)*; Christophe Tzourio 
(University of Bordeaux, France)*; Peter Ueda (Harvard T H Chan School 
of Public Health, USA)*; Flora M Ukoli (Meharry Medical College, 
USA)*; Hanno Ulmer (Medical University of Innsbruck, Austria)*; 
Gonzalo Valdivia (Pontiﬁ cia Universidad Católica de Chile, Chile)*; 
Irene G M van Valkengoed (Academic Medical Center of University of 
Amsterdam, Netherlands)*; Dirk Vanderschueren (Katholieke 
Universiteit Leuven, Belgium)*; Diego Vanuzzo (Centro di Prevenzione 
Cardiovascolare, Italy)*; Tomas Vega (Consejería de Sanidad, Junta de 
Castilla y León, Spain)*; Gustavo Velasquez-Melendez (Universidade 
Federal de Minas Gerais, Brazil)*; Giovanni Veronesi (University of 
Insubria, Italy)*; Monique Verschuren (National Institute for Public 
Health and the Environment, Netherlands)*; Jesus Vioque (Universidad 
Miguel Hernandez, Spain)*; Jyrki Virtanen (University of Eastern 
Finland, Finland)*; Sophie Visvikis-Siest (INSERM, France)*; 
Bharathi Viswanathan (Ministry of Health, Seychelles)*; 
Peter Vollenweider (Lausanne University Hospital, Switzerland)*; 
Sari Voutilainen (University of Eastern Finland, Finland)*; 
Alisha N Wade (University of the Witwatersrand, South Africa)*; 
Aline Wagner (University of Strasbourg, France)*; Janette Walton 
(University College Cork, Ireland)*; Wan Nazaimoon Wan Mohamud 
(Institute for Medical Research, Malaysia)*; Ming-Dong Wang (Public 
Health Agency of Canada, Canada)*; Ya Xing Wang (Beijing Tongren 
Hospital, China)*; S Goya Wannamethee (University College London, 
UK)*; Deepa Weerasekera (Ministry of Health, New Zealand)*; 
Peter H Whincup (St George’s, University of London, UK)*; 
Kurt Widhalm (Medical University of Vienna, Austria)*; Andrzej Wiecek 
(Medical University of Silesia, Poland)*; Rainford J Wilks (The University 
of the West Indies, Jamaica)*; Johann Willeit (Medical University 
Innsbruck, Austria)*; Bogdan Wojtyniak (National Institute of Hygiene, 
Poland)*; Tien Yin Wong (Duke-NUS Graduate Medical School, 
Singapore)*; Jean Woo (The Chinese University of Hong Kong, China)*; 
Mark Woodward (University of Sydney, Australia; University of Oxford, 
UK)*; Aleksander Giwercman Wu (Lund University, Sweden)*; 
Frederick C Wu (University of Manchester, UK)*; Shou Ling Wu (Kailuan 
General Hospital, China)*; Haiquan Xu (Institute of Food and Nutrition 
Development of Ministry of Agriculture, China)*; Xiaoguang Yang 
(Chinese Center for Disease Control and Prevention, China)*; 
Xingwang Ye (University of Chinese Academy of Sciences, China)*; 
Akihiro Yoshihara (Niigata University, Japan)*; 
Novie O Younger-Coleman (The University of the West Indies, Jamaica)*; 
Sabina Zambon (University of Padova, Italy)*; Abdul Hamid Zargar 
(Center for Diabetes and Endocrine Care, India)*; Tomasz Zdrojewski 
(Medical University of Gdansk, Poland)*; Wenhua Zhao (Chinese Center 
for Disease Control and Prevention, China)*; Yingfeng Zheng (Singapore 
Eye Research Institute, Singapore)*.
Articles
www.thelancet.com/diabetes-endocrinology   Vol 3   August 2015 635
Declaration of interests
JJM has received funding from Medtronics Foundation outside the 
submitted work. DM has received grants to her institution from Novartis 
Pharmaceutical, Novo Nordisk Pharmaceutical, Pharmacia and Upjohn, 
Pﬁ zer, Sanoﬁ  Synthelabo, and Servier Laboratories. JES has received 
grants to his institution from Abbott, Alphapharm, AstraZeneca, Aventis 
Pharmaceutical, Eli Lilly, GlaxoSmithKline, Janssen-Cilag, Merck Lipha, 
Merck Sharp & Dohme, Novartis Pharmaceutical, Novo Nordisk 
Pharmaceutical, Pharmacia and Upjohn, Pﬁ zer, Sanoﬁ  Synthelabo, and 
Servier Laboratories. All other Pooled Analysis and Writing Group 
members report no competing interests.
Acknowledgments
This study was funded by the Wellcome Trust and US National Institutes 
of Health (DK090435). The authors alone are responsible for the views 
expressed in this Article and they do not necessarily represent the views, 
decisions, or policies of the institutions with which they are aﬃ  liated.
References
 1 Danaei G, Finucane MM, Lu Y, et al. National, regional, and global 
trends in fasting plasma glucose and diabetes prevalence since 
1980: systematic analysis of health examination surveys and 
epidemiological studies with 370 country-years and 2·7 million 
participants. Lancet 2011; 378: 31–40.
 2 Finucane MM, Stevens GA, Cowan MJ, et al. National, regional, 
and global trends in body-mass index since 1980: systematic 
analysis of health examination surveys and epidemiological studies 
with 960 country-years and 9·1 million participants. Lancet 2011; 
377: 557–67.
 3 Stevens GA, Singh GM, Lu Y, et al. National, regional, and global 
trends in adult overweight and obesity prevalences. 
Popul Health Metr 2012; 10: 22.
 4 Kontis V, Mathers CD, Rehm J, et al. Contribution of six risk factors 
to achieving the 25×25 non-communicable disease mortality 
reduction target: a modelling study. Lancet 2014; 384: 427–37.
 5 Global Burden of Metabolic Risk Factors for Chronic Diseases 
Collaboration. Cardiovascular disease, chronic kidney disease, and 
diabetes mortality burden of cardiometabolic risk factors from 1980 
to 2010: a comparative risk assessment. 
Lancet Diabetes Endocrinol 2014; 2: 634–47.
 6 Zimmet PZ, Magliano DJ, Herman WH, Shaw JE. Diabetes: a 21st 
century challenge. Lancet Diabetes Endocrinol 2014; 2: 56–64.
 7 Yach D, Stuckler D, Brownell KD. Epidemiologic and economic 
consequences of the global epidemics of obesity and diabetes. 
Nat Med 2006; 12: 62–66.
 8 International Diabetes Federation. IDF Diabetes Atlas, 6th edn. 
Brussels: International Diabetes Federation; 2013.
 9 WHO. Deﬁ nition, diagnosis and classiﬁ cation of diabetes mellitus 
and its complications: report of a WHO consultation. Part 1: 
Diagnosis and classiﬁ cation of diabetes mellitus. Geneva: World 
Health Organization, 1999.
 10 WHO. Deﬁ nition and diagnosis of diabetes mellitus and 
intermediate hyperglycemia: report of a WHO/IDF consultation. 
Geneva: World Health Organization, 2006.
 11 WHO. Use of glycated haemoglobin (HbA1c) in the diagnosis of 
diabetes mellitus: abbreviated report of a WHO consultation. 
Geneva: World Health Organization, 2011.
 12 Expert Committee on the Diagnosis and Classiﬁ cation of Diabetes 
Mellitus. Report of the expert committee on the diagnosis and 
classiﬁ cation of diabetes mellitus. Diabetes Care 2003; 
26 (suppl 1): S5–20.
 13 American Diabetes Association. Standards of medical care in 
diabetes—2014. Diabetes Care 2014; 37 (suppl 1): S14–80.
 14 American Diabetes Association. Diagnosis and classiﬁ cation of 
diabetes mellitus. Diabetes Care 2014; 37 (suppl 1): S81–90.
 15 Barrett-Connor E. The oral glucose tolerance test, revisited. 
Eur Heart J 2002; 23: 1229–31.
 16 Tobias M. Global control of diabetes: information for action. 
Lancet 2011; 378: 3–4.
 17 Hare MJ, Shaw JE, Zimmet PZ. Current controversies in the use of 
haemoglobin A1c. J Intern Med 2012; 271: 227–36.
 18 WHO. Global action plan for the prevention and control of non-
communicable diseases 2013–2020. Geneva: World Health 
Organization, 2013.
 19 Shibata K, Suzuki S, Sato J, et al. Diagnostic accuracy of 
glycohemoglobin A1c (HbA1c) for postprandial hyperglycemia was 
equivalent to that of fasting blood glucose. J Clin Epidemiol 2005; 
58: 1052–57.
 20 Kim HK, Bae SJ, Choe J. Impact of HbA1c criterion on the 
detection of subjects with increased risk for diabetes among health 
check-up recipients in Korea. Diabetes Metab J 2012; 36: 151–56.
 21 Mo M, Zhong W, Zhao G, et al. Combining glycosylated 
hemoglobin A1c and fasting plasma glucose for diagnosis of type 2 
diabetes in Chinese adults. BMC Endocr Disord 2013; 13: 44.
 22 Wiener K, Roberts NB. The relative merits of haemoglobin A1c and 
fasting plasma glucose as ﬁ rst-line diagnostic tests for diabetes 
mellitus in non-pregnant subjects. Diabet Med 1998; 15: 558–63.
 23 Vlaar EM, Admiraal WM, Busschers WB, et al. Screening South 
Asians for type 2 diabetes and prediabetes: (1) comparing oral 
glucose tolerance and haemoglobin A1c test results and (2) 
comparing the two sets of metabolic proﬁ les of individuals 
diagnosed with these two tests. BMC Endocr Disord 2013; 13: 8.
 24 Mannucci E, Ognibene A, Sposato I, et al. Fasting plasma glucose 
and glycated haemoglobin in the screening of diabetes and 
impaired glucose tolerance. Acta Diabetol 2003; 40: 181–86.
 25 Carson AP, Reynolds K, Fonseca VA, Muntner P. Comparison of 
A1C and fasting glucose criteria to diagnose diabetes among US 
adults. Diabetes Care 2010; 33: 95–97.
 26 Adamu AN. Comparative performance of HbA1c 6.5% for FPG 
>/=7.0 vs 2hr PG>/=11.1 criteria for diagnosis of type 2 diabetes. 
Afr Health Sci 2011; 11: 421–26.
 27 Cederberg H, Saukkonen T, Laakso M, et al. Postchallenge glucose, 
A1C, and fasting glucose as predictors of type 2 diabetes and 
cardiovascular disease: a 10-year prospective cohort study. 
Diabetes Care 2010; 33: 2077–83.
 28 Kramer CK, Araneta MR, Barrett-Connor E. A1C and diabetes 
diagnosis: The Rancho Bernardo Study. Diabetes Care 2010; 33: 101–03.
 29 Li HY, Ma WY, Wei JN, et al. Hemoglobin A1c for the diagnosis of 
diabetes: To replace or to guide oral glucose tolerance tests? 
J Diabetes Investig 2012; 3: 259–65.
 30 Pajunen P, Peltonen M, Eriksson JG, et al. HbA(1c) in diagnosing 
and predicting Type 2 diabetes in impaired glucose tolerance: the 
Finnish Diabetes Prevention Study. Diabet Med 2011; 28: 36–42.
 31 Piette JD, Milton EC, Aiello AE, Mendoza-Avelares MO, Herman WH. 
Comparison of three methods for diabetes screening in a rural clinic 
in Honduras. Rev Panam Salud Publica 2010; 28: 49–57.
 32 Pinelli NR, Jantz AS, Martin ET, Jaber LA. Sensitivity and speciﬁ city 
of glycated hemoglobin as a diagnostic test for diabetes and 
prediabetes in Arabs. J Clin Endocrinol Metab 2011; 96: E1680–83.
 33 Selvin E, Steﬀ es MW, Gregg E, Brancati FL, Coresh J. Performance 
of A1C for the classiﬁ cation and prediction of diabetes. 
Diabetes Care 2011; 34: 84–89.
 34 Olson DE, Rhee MK, Herrick K, Ziemer DC, Twombly JG, 
Phillips LS. Screening for diabetes and pre-diabetes with proposed 
A1C-based diagnostic criteria. Diabetes Care 2010; 33: 2184–89.
 35 Almoosawi S, Cole D, Nicholson S, et al. Biomarkers of diabetes 
risk in the National Diet and Nutrition Survey rolling programme 
(2008–2011). J Epidemiol Community Health 2014; 68: 51–56.
 36 Droumaguet C, Balkau B, Simon D, et al. Use of HbA1c in 
predicting progression to diabetes in French men and women: data 
from an Epidemiological Study on the Insulin Resistance Syndrome 
(DESIR). Diabetes Care 2006; 29: 1619–25.
 37 Engelgau MM, Thompson TJ, Herman WH, et al. Comparison of 
fasting and 2-hour glucose and HbA1c levels for diagnosing 
diabetes. Diagnostic criteria and performance revisited. 
Diabetes Care 1997; 20: 785–91.
 38 Hjellestad ID, Astor MC, Nilsen RM, Softeland E, Jonung T. HbA(1)c 
versus oral glucose tolerance test as a method to diagnose diabetes 
mellitus in vascular surgery patients. Cardiovasc Diabetol 2013; 12: 79.
 39 Hu YM, Liu W, Chen YW, et al. Combined use of fasting plasma 
glucose and glycated hemoglobin A1c in the screening of diabetes 
and impaired glucose tolerance. Acta Diabetol 2010; 47: 231–36.
 40 Balkau B, Soulimane S, Lange C, et al. Are the same clinical risk 
factors relevant for incident diabetes deﬁ ned by treatment, fasting 
plasma glucose, and HbA1c? Diabetes Care 2011; 34: 957–59.
 41 Soulimane S, Simon D, Shaw J, et al. HbA1c, fasting plasma 
glucose and the prediction of diabetes: Inter99, AusDiab 
and D.E.S.I.R. Diabetes Res Clin Pract 2012; 96: 392–99.
Articles
636 www.thelancet.com/diabetes-endocrinology   Vol 3   August 2015
 42 Soulimane S, Simon D, Shaw JE, et al. Comparing incident diabetes 
as deﬁ ned by fasting plasma glucose or by HbA(1c). The AusDiab, 
Inter99 and DESIR studies. Diabet Med 2011; 28: 1311–18.
 43 de Vegt F, Dekker JM, Stehouwer CD, Nijpels G, Bouter LM, 
Heine RJ. Similar 9-year mortality risks and reproducibility for the 
World Health Organization and American Diabetes Association 
glucose tolerance categories: the Hoorn Study. Diabetes Care 2000; 
23: 40–44.
 44 Wild SH, Smith FB, Lee AJ, Fowkes FG. Criteria for previously 
undiagnosed diabetes and risk of mortality: 15-year follow-up of the 
Edinburgh Artery Study cohort. Diabet Med 2005; 22: 490–96.
 45 Zhang YH, Ma WJ, Thomas GN, et al. Diabetes and pre-diabetes as 
determined by glycated haemoglobin A1c and glucose levels in a 
developing southern Chinese population. PLoS One 2012; 
7: e37260.
 46 Cowie CC, Rust KF, Byrd-Holt DD, et al. Prevalence of diabetes and 
high risk for diabetes using A1C criteria in the U.S. population in 
1988-2006. Diabetes Care 2010; 33: 562–68.
 47 Ito C, Maeda R, Ishida S, Sasaki H, Harada H. Correlation among 
fasting plasma glucose, two-hour plasma glucose levels in OGTT 
and HbA1c. Diabetes Res Clin Pract 2000; 50: 225–30.
 48 Kharroubi AT, Darwish HM, Abu Al-Halaweh AI, Khammash UM. 
Evaluation of glycated hemoglobin (HbA1c) for diagnosing type 2 
diabetes and prediabetes among Palestinian Arab population. 
PLoS One 2014; 9: e88123.
 49 Bao Y, Ma X, Li H, et al. Glycated haemoglobin A1c for diagnosing 
diabetes in Chinese population: cross sectional epidemiological 
survey. BMJ 2010; 340: c2249.
 50 Davidson MB. Diagnosing diabetes with glucose criteria: 
worshiping a false God. Diabetes Care 2011; 34: 524–26.
 51 Nazir A, Papita R, Anbalagan VP, Anjana RM, Deepa M, Mohan V. 
Prevalence of diabetes in Asian Indians based on glycated 
hemoglobin and fasting and 2-H post-load (75-g) plasma glucose 
(CURES-120). Diabetes Technol Ther 2012; 14: 665–68.
 52 Rathmann W, Kowall B, Tamayo T, et al. Hemoglobin A1c and 
glucose criteria identify diﬀ erent subjects as having type 2 diabetes 
in middle-aged and older populations: The KORA S4/F4 Study. 
Ann Med 2012; 44: 170–77.
 53 Blunt BA, Barrettconnor E, Wingard DL. Evaluation of fasting 
plasma-glucose as screening-test for Niddm in older adults—
Rancho Bernardo Study. Diabetes Care 1991; 14: 989–93.
 54 Nakagami T, Tominaga M, Nishimura R, et al. Is the measurement 
of glycated hemoglobin A1c alone an eﬃ  cient screening test for 
undiagnosed diabetes? Japan National Diabetes Survey. 
Diabetes Res Clin Pract 2007; 76: 251–56.
 55 Munera-Jaramillo MI, Restrepo-Lozada MA, Gomez-Bahamon LM, 
Mesa-Suarez Ddel R, Ramirez-Puerta BS. Glycosylated haemoglobin 
A1c compared to fasting plasma glucose in outpatients referred to a 
medical laboratory. Rev Salud Publica (Bogota) 2011; 
13: 980–89 (in Spanish).
 56 Araneta MR, Grandinetti A, Chang HK. A1C and diabetes diagnosis 
among Filipino Americans, Japanese Americans, and Native 
Hawaiians. Diabetes Care 2010; 33: 2626–28.
 57 Homko CJ, Zamora LC, Kerper MM, Mozzoli M, Kresge K, 
Boden G. A single a1c >= 6.5% accurately identiﬁ es type 2 
diabetes/impaired glucose tolerance in African Americans. 
J Prim Care Community Health 2012; 3: 235–38.
 58 Khoo J, Tay TL, Foo JP, et al. Sensitivity of A1C to diagnose diabetes 
is decreased in high-risk older Southeast Asians. 
J Diabetes Complications 2012; 26: 99–101.
 59 Peter A, Fritsche A, Stefan N, Heni M, Haring HU, Schleicher E. 
Diagnostic value of hemoglobin A1c for type 2 diabetes mellitus 
in a population at risk. Exp Clin Endocrinol Diabetes 2011; 
119: 234–37.
 60 van ‘t Riet E, Alssema M, Rijkelijkhuizen JM, Kostense PJ, 
Nijpels G, Dekker JM. Relationship between A1C and glucose levels 
in the general Dutch population: the new Hoorn study. 
Diabetes Care 2010; 33: 61–66.
 61 Lipska KJ, De Rekeneire N, Van Ness PH, et al. Identifying 
dysglycemic states in older adults: implications of the emerging use 
of hemoglobin A1c. J Clin Endocrinol Metab 2010; 95: 5289–95.
 62 DECODE Study Group. Will new diagnostic criteria for diabetes 
mellitus change phenotype of patients with diabetes? Reanalysis of 
European epidemiological data. BMJ 1998; 317: 371–75.
 63 DECODE Study Group. Age- and sex-speciﬁ c prevalences of 
diabetes and impaired glucose regulation in 13 European cohorts. 
Diabetes Care 2003; 26: 61–69.
 64 Qiao Q, Hu G, Tuomilehto J, et al. Age- and sex-speciﬁ c prevalence 
of diabetes and impaired glucose regulation in 11 Asian cohorts. 
Diabetes Care 2003; 26: 1770–80.
 65 Shaw JE, de Courten M, Boyko EJ, Zimmet PZ. Impact of new 
diagnostic criteria for diabetes on diﬀ erent populations. 
Diabetes Care 1999; 22: 762–66.
 66 DECODE Study Group. Is fasting glucose suﬃ  cient to deﬁ ne 
diabetes? Epidemiological data from 20 European studies. 
Diabetologia 1999; 42: 647–54.
 67 Christensen DL, Witte DR, Kaduka L, et al. Moving to an A1C-
based diagnosis of diabetes has a diﬀ erent impact on 
prevalence in diﬀ erent ethnic groups. Diabetes Care 2010; 
33: 580–82.
 68 Ziemer DC, Kolm P, Weintraub WS, et al. Glucose-independent, 
black-white diﬀ erences in hemoglobin A1c levels: a cross-sectional 
analysis of 2 studies. Ann Intern Med 2010; 152: 770–77.
 69 Kumar PR, Bhansali A, Ravikiran M, et al. Utility of glycated 
hemoglobin in diagnosing type 2 diabetes mellitus: a community-
based study. J Clin Endocrinol Metab 2010; 95: 2832–35.
 70 Selvin E, Steﬀ es MW, Ballantyne CM, Hoogeveen RC, Coresh J, 
Brancati FL. Racial diﬀ erences in glycemic markers: a cross-
sectional analysis of community-based data. Ann Intern Med 2011; 
154: 303–09.
 71 American Diabetes Association. Implications of the Diabetes 
Control and Complications Trial. Diabetes Care 2000; 
23 (suppl 1): S24–26.
 72 Cowie CC, Rust KF, Ford ES, et al. Full accounting of diabetes and 
pre-diabetes in the U.S. population in 1988-1994 and 2005-2006. 
Diabetes Care 2009; 32: 287–94.
 73 Schwarz G. Estimating dimension of a model. Ann Stat 1978; 
6: 461–64.
 74 Di Cesare M, Khang YH, Asaria P, et al. Inequalities in non-
communicable diseases and eﬀ ective responses. Lancet 2013; 
381: 585–97.
 75 Cohen J, Cohen P, West SG, Aiken LS. Applied multiple regression/
correlation analysis for the behavioral sciences. Routledge, 2013.
 76 DerSimonian R, Laird N. Meta-analysis in clinical trials. 
Control Clin Trials 1986; 7: 177–88.
 77 Sacks DB, Arnold M, Bakris GL, et al. Guidelines and 
recommendations for laboratory analysis in the diagnosis and 
management of diabetes mellitus. Clin Chem 2011; 57: e1–47.
78 Snijders TAB, Bosker RJ. Multilevel Analysis: An Introduction to 
Basic and Advanced Multilevel Modeling: SAGE Publications, 2011.
 79 Nakagawa S, Schielzeth H. A general and simple method for 
obtaining R2 from generalized linear mixed-eﬀ ects models. 
Methods Ecol Evol 2013; 4: 133–42.
80 Qiao Q, Tuomilehto J, Balkau B, et al. Are insulin resistance, 
impaired fasting glucose and impaired glucose tolerance all equally 
strongly related to age? Diabet Med 2005; 22: 1476–81.
 81 Zamboni M, Armellini F, Harris T, et al. Eﬀ ects of age on body fat 
distribution and cardiovascular risk factors in women. 
Am J Clin Nutr 1997; 66: 111–15.
 82 Stevens GA, Finucane MM, De-Regil LM, et al. Global, regional, 
and national trends in haemoglobin concentration and prevalence 
of total and severe anaemia in children and pregnant and non-
pregnant women for 1995-2011: a systematic analysis of population-
representative data. Lancet Glob Health 2013; 1: e16–25.
 83 Colagiuri S, Lee CM, Wong TY, et al. Glycemic thresholds for 
diabetes-speciﬁ c retinopathy: implications for diagnostic criteria for 
diabetes. Diabetes Care 2011; 34: 145–50.
 84 Emerging Risk Factors Collaboration. Glycated hemoglobin 
measurement and prediction of cardiovascular disease. JAMA 2014; 
311: 1225–33.
 85 Hare MJ, Magliano DJ, Zimmet PZ, et al. Glucose-independent 
ethnic diﬀ erences in HbA1c in people without known diabetes. 
Diabetes Care 2013; 36: 1534–40.
 86 Choi SH, Kim TH, Lim S, Park KS, Jang HC, Cho NH. Hemoglobin 
A1c as a diagnostic tool for diabetes screening and new-onset 
diabetes prediction: a 6-year community-based prospective study. 
Diabetes Care 2011; 34: 944–49.
Articles
www.thelancet.com/diabetes-endocrinology   Vol 3   August 2015 637
 87 Lee H, Oh JY, Sung YA, et al. Optimal hemoglobin A1C cutoﬀ  value 
for diagnosing type 2 diabetes mellitus in Korean adults. 
Diabetes Res Clin Pract 2013; 99: 231–36.
 88 Nomura K, Inoue K, Akimoto K. A two-step screening, 
measurement of HbA1c in association with FPG, may be useful in 
predicting diabetes. PLoS One 2012; 7: e36309.
 89 Kim JM, Hong JW, Won JC, et al. Glycated hemoglobin value for 
fasting plasma glucose of 126 mg/dL in Korean: The 2011 Korea 
National Health and Nutrition Examination Survey. Diabetes Metab J 
2014; 38: 480–83.
 90 Son JI, Rhee SY, Woo JT, et al. Hemoglobin a1c may be an 
inadequate diagnostic tool for diabetes mellitus in anemic subjects. 
Diabetes Metab J 2013; 37: 343–48.
 91 The Diabetes Control and Complications Trial Research Group. 
The eﬀ ect of intensive treatment of diabetes on the 
development and progression of long-term complications in 
insulin-dependent diabetes mellitus. The Diabetes Control and 
Complications Trial Research Group. N Engl J Med 1993; 
329: 977–86.
 92 UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-
glucose control with sulphonylureas or insulin compared with 
conventional treatment and risk of complications in patients with 
type 2 diabetes (UKPDS 33). Lancet 1998; 352: 837–53.
 93 Little RR. Glycated hemoglobin standardization—National 
Glycohemoglobin Standardization Program (NGSP) perspective. 
Clin Chem Lab Med 2003; 41: 1191–98.
 94 Hoelzel W, Weykamp C, Jeppsson JO, et al. IFCC reference system 
for measurement of hemoglobin A1c in human blood and the 
national standardization schemes in the United States, Japan, and 
Sweden: a method-comparison study. Clin Chem 2004; 50: 166–74.
 95 American Diabetes Association, European Association for the Study 
of Diabetes, International Federation of Clinical Chemistry and 
Laboratory Medicine, International Diabetes Federation. Consensus 
statement on the worldwide standardisation of the HbA1c 
measurement. Diabetologia 2007; 50: 2042–43.
 96 Hanas R, John G. 2010 consensus statement on the worldwide 
standardization of the hemoglobin A1c measurement. 
Diabet Med 2010; 27: 737–38.
 97 Hanas R, John WG. 2013 update on the worldwide standardization 
of the HbA1c measurement. Diabet Med 2013; 30: 885–86.
 98 National Glycohemoglobin Standardization Program. International 
Federation of Clinical Chemistry (IFCC) Standardization of HbA1c. 
http://www.ngsp.org/docs/IFCCstd.pdf (accessed Dec 29, 2014).
 99 Simon D, Senan C, Balkau B, Saint-Paul M, Thibult N, Eschwege E. 
Reproducibility of HbA1c in a healthy adult population: the Telecom 
Study. Diabetes Care 1999; 22: 1361–63.
 100 Little RR, Rohlﬁ ng CL, Sacks DB. Status of hemoglobin A1c 
measurement and goals for improvement: from chaos to order for 
improving diabetes care. Clin Chem 2011; 57: 205–14.
 101 Hardikar PS, Joshi SM, Bhat DS, et al. Spuriously high prevalence 
of prediabetes diagnosed by HbA(1c) in young indians partly 
explained by hematological factors and iron deﬁ ciency anemia. 
Diabetes Care 2012; 35: 797–802.
 102 DECODE study group. Glucose tolerance and mortality: 
comparison of WHO and American Diabetes Association diagnostic 
criteria. Lancet 1999; 354: 617–21.
 103 Nakagami T, DECODA Study Group. Hyperglycaemia and mortality 
from all causes and from cardiovascular disease in ﬁ ve populations 
of Asian origin. Diabetologia 2004; 47: 385–94.
